Evidence map›Paper›PMID 27117590›Full record

ArticleRadiation oncology (London, England)2016

Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer.

Tru-Khang T Dinh, Wojciech Fendler, Justyna Chałubińska-Fendler, Sanket S Acharya, Colin O'Leary, Peter V Deraska, Alan D D'Andrea, Dipanjan Chowdhury, David Kozono

Open access · goldAbstract read
In one paragraph

Article in Radiation oncology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Sex differences in radiation research.International journal of radiation biology · 2024
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Tru-Khang T DinhHarvard Medical School, 25 Shattuck St, Boston, MA, 02115, USA.
Wojciech FendlerDepartment of Biostatistics and Translational Medicine, Medical University of Łódź, Al. Kościuszki 4, 90-419, Łódź, Poland.
Justyna Chałubińska-FendlerDepartment of Radiation Oncology, Medical University of Łódź, Al. Kościuszki 4, 90-419, Łódź, Poland.
Sanket S AcharyaDepartment of Radiation Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.
Colin O'LearyDepartment of Radiation Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.
Peter V DeraskaDepartment of Radiation Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.
Alan D D'AndreaHarvard Medical School, 25 Shattuck St, Boston, MA, 02115, USA. alan_dandrea@dfci.harvard.edu.
Dipanjan ChowdhuryHarvard Medical School, 25 Shattuck St, Boston, MA, 02115, USA. dipanjan_chowdhury@dfci.harvard.edu.
David KozonoHarvard Medical School, 25 Shattuck St, Boston, MA, 02115, USA. dkozono@lroc.harvard.edu.
Dana-Farber Cancer Institute · USMedical University of Lodz · PLLemuel Shattuck Hospital · US

Funding

Characterization of lung cancer radiosensitizers from genome-wide RNAi screensK08CA172354 · NCI · DANA-FARBER CANCER INST · PI KOZONO, DAVID · 2013 to 2017
$883k
NCI NIH HHS K08 CA172354
6 · The paper itself

Abstract

backgroundRisk of normal tissue toxicity limits the amount of thoracic radiation therapy (RT) that can be routinely prescribed to treat non-small cell lung cancer (NSCLC). An early biomarker of response to thoracic RT may provide a way to predict eventual toxicities-such as radiation pneumonitis-during treatment, thereby enabling dose adjustment before the symptomatic onset of late effects. MicroRNAs (miRNAs) were studied as potential serological biomarkers for thoracic RT. As a first step, we sought to identify miRNAs that correlate with delivered dose and standard dosimetric factors.

methodsWe performed miRNA profiling of plasma samples obtained from five patients with Stage IIIA NSCLC at five dose-points each during radical thoracic RT. Candidate miRNAs were then assessed in samples from a separate cohort of 21 NSCLC patients receiving radical thoracic RT. To identify a cellular source of circulating miRNAs, we quantified in vitro miRNA expression intracellularly and within secreted exosomes in five NSCLC and stromal cell lines.

resultsmiRNA profiling of the discovery cohort identified ten circulating miRNAs that correlated with delivered RT dose as well as other dosimetric parameters such as lung V20. In the validation cohort, miR-29a-3p and miR-150-5p were reproducibly shown to decrease with increasing radiation dose. Expression of miR-29a-3p and miR-150-5p in secreted exosomes decreased with radiation. This was concomitant with an increase in intracellular levels, suggesting that exosomal export of these miRNAs may be downregulated in both NSCLC and stromal cells in response to radiation.

conclusionsmiR-29a-3p and miR-150-5p were identified as circulating biomarkers that correlated with delivered RT dose. miR-150 has been reported to decrease in the circulation of mammals exposed to radiation while miR-29a has been associated with fibrosis in the human heart, lungs, and kidneys. One may therefore hypothesize that outlier levels of circulating miR-29a-3p and miR-150-5p may eventually help predict unexpected responses to radiation therapy, such as toxicity.

Indexed as

BiomarkersCarcinoma, Non-Small-Cell LungCell Line, TumorCohort StudiesCulture Media, ConditionedDown-RegulationExosomesFibrosisGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLungLung NeoplasmsMicroRNAsRadiometryRadiotherapyBiomarkersCulture Media, ConditionedMicroRNAsMIR150, humanMIRN29a microRNA, humanmicroRNAsNon-small cell lung cancerRadiotherapyThoracic

Identifiers

PMID27117590
PMCPMC4847218
OpenAlexW2342933435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.